Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211698 | 0.87 | L3MBTL1 (0.61) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL19911374 | 0.81 | FGFR1 (0.57) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL19911402 | 0.80 | PKM (0.54) | L3MBTL1FGFR1ALDH1A1HTTPKM | |
| SCHEMBL19911399 | 0.80 | FGFR1 (0.60) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL8425553 | 0.80 | FGFR1 (0.60) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL8337275 | 0.80 | FGFR1 (0.60) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL2160267 | 0.80 | FGFR1 (0.60) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL19185810 | 0.80 | L3MBTL1 (1.00) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL19911390 | 0.80 | FGFR1 (0.56) | L3MBTL1FGFR1ALDH1A1HTTHPGD | |
| SCHEMBL7036153 | 0.80 | FGFR1 (0.56) | L3MBTL1FGFR1ALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430738-A | Catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| US-12037636-B2 | Polynucleotide synthesis method, kit and system | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-07-16 | — | — | US | disclosed |
| CN-113896744-B | Selective EGFR inhibitor | 成都先导药物开发股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117430738-A | Catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| WO-2017155816-A1 | QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153952-A1 | 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| US-8486962-B2 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2013-07-16 | — | — | US | disclosed |
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006048251-A1 | ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048249-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1655295-A1 | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1655297-A1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | L3MBTL1 2717/4885FGFR1 34/4885ALDH1A1 2915/4885 |
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | L3MBTL1 4361/4885FGFR1 15/4885ALDH1A1 1492/4885 |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | L3MBTL1 4468/4885FGFR1 19/4885ALDH1A1 1448/4885 |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | FLT1, KDR, FLT4 | L3MBTL1 4361/4885FGFR1 15/4885ALDH1A1 1492/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | L3MBTL1 2127/4885FGFR1 1543/4885ALDH1A1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.